The latest price target for INmune Bio (NASDAQ:INMB) was reported by LUCID CAPITAL MARKETS on March 11, 2026. The analyst firm set a price target for $9.00 expecting INMB to rise to within 12 months (a possible 643.80% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for INmune Bio (NASDAQ:INMB) was provided by LUCID CAPITAL MARKETS, and INmune Bio upgraded their buy rating.

The last upgrade for INmune Bio Inc happened on March 11, 2026 when LUCID CAPITAL MARKETS raised their price target to $9. LUCID CAPITAL MARKETS previously had a neutral for INmune Bio Inc.

The last downgrade for INmune Bio Inc happened on July 1, 2025 when BTIG changed their price target from N/A to N/A for INmune Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of INmune Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for INmune Bio was filed on March 11, 2026 so you should expect the next rating to be made available sometime around March 11, 2027.

While ratings are subjective and will change, the latest INmune Bio (INMB) rating was a upgraded with a price target of $2.00 to $9.00. The current price INmune Bio (INMB) is trading at is $1.21, which is out of the analyst’s predicted range.